Expanded access trials: Trial Insights

Filters: Phase: Expanded access Clear all

1,072 trials match Source: ClinicalTrials.gov registrations

Trials started per year
Category	Trials
2000	1
2001	1
2002	1
2003	6
2004	5
2005	3
2006	5
2007	4
2008	5
2009	6
2010	5
2011	2
2012	6
2013	6
2014	5
2015	3
2016	1

Trials by status
Category	Trials
No longer available	538
Available	252
Approved for marketing	244
Temporarily not available	38

Top lead sponsors
Category	Trials
Novartis Pharmaceuticals	43
Bristol-Myers Squibb	27
Pfizer	22
Janssen Research & Development, LLC	19
AbbVie	18
Regeneron Pharmaceuticals	18
Hope Biosciences Research Foundation	16
Eli Lilly and Company	15
Amgen	12
Boehringer Ingelheim	12

Top conditions
Category	Trials
Neoplasms	37
Carcinoma, Non-Small-Cell Lung	35
Recurrence	35
Multiple Myeloma	32
COVID-19	31
Prostatic Neoplasms	28
Leukemia, Myeloid, Acute	21
Melanoma	21
Breast Neoplasms	19
Glioblastoma	16

Trials

Showing 76 to 100 of 1,072. Each trial links to its page on Pharma Observatory.

TMC114-C226: An Early Access Program to Evaluate the Long-term Safety and Tolerability of TMC114 Combined With a Low Dose of Ritonavir (TMC114/r) With Other Antiretrovirals, for HIV-1 Infected Patients Who Have Failed Multiple Antiretroviral Regimens. NCT00245739Expanded accessApproved for marketingTibotec Pharmaceuticals, Ireland
The TMC125-C214 Study Provides Early Access to TMC125 for HIV-1 Infected Patients Who Have Failed Multiple Antiretroviral Regimens and Will Also Gather Information on the Long-term Safety and Tolerability of TMC125 Combined With Other Antiretroviral Drugs NCT00354627Expanded accessApproved for marketingTibotec Pharmaceuticals, Ireland
Early Access of MK0518 in Combination With an Optimized Background Antiretroviral Therapy (0518-023) NCT00377065Expanded accessApproved for marketingMerck Sharp & Dohme LLC
Compassionate Use of Vorinostat for the Treatment of Patients With Advanced Cutaneous T-Cell Lymphoma (0683-042) NCT00419367Expanded accessNo longer availableMerck Sharp & Dohme LLC
The Paroxysmal Nocturnal Hemoglobinuria Early Access Treatment Protocol NCT00438789Expanded accessApproved for marketingAlexion Pharmaceuticals, Inc.
Expanded Access for Dasatinib NCT00454753Expanded accessNo longer availableBristol-Myers Squibb
Phone Intervention for Alcohol (ETOH) Use in Emergency Department Motor Vehicle Crash (ED MVC) Patients NCT00457548Expanded accessAvailableRhode Island Hospital
Treatment Protocol of Voraxaze for Patients Experiencing or at Risk of Methotrexate Toxicity NCT00481559Expanded accessApproved for marketingBTG International Inc.
Sapropterin Expanded Access Program NCT00484991Expanded accessApproved for marketingBioMarin Pharmaceutical
Compassionate Use Trial for Unresectable Melanoma With Ipilimumab NCT00495066Expanded accessNo longer availableBristol-Myers Squibb
Aztreonam Lysine for Inhalation in Patients With Cystic Fibrosis and Pseudomonas Aeruginosa Airway Infection NCT00499720Expanded accessApproved for marketingGilead Sciences
Compassionate Use of Sodium Stibogluconate (Pentostam) for Cutaneous and Mucocutaneous New World Leishmaniasis NCT00508963Expanded accessNo longer availableUniversity of California, San Francisco
A Treatment Investigational New Drug (tIND) Program of Tegaserod in Women With Irritable Bowel Syndrome With Constipation or With Chronic Idiopathic Constipation NCT00511771Expanded accessNo longer availableNovartis
Dose-Dense Therapy in Aggressive Lymphoma NCT00517894Expanded accessNo longer availableArbeitsgemeinschaft medikamentoese Tumortherapie
Alglucosidase Alfa Temporary Access Program NCT00520143Expanded accessApproved for marketingGenzyme, a Sanofi Company
Clinical Evaluation of Cardiac Resynchronization Therapy (CRT) Using the Ovatio CRT Implantable Cardioverter-defibrillator (ICD) System NCT00528320Expanded accessApproved for marketingELA Medical, Inc.
Compassionate Use of Metvix® (Methyl Aminolevulinate) Photodynamic Therapy (PDT) in Subjects With Field Actinic Keratoses, Large/Multiple Superficial Basal Cell Carcinomas (BCCs), or Bowen's Disease NCT00535080Expanded accessNo longer availableGalderma R&D
Prospective Analysis and Comparison of Stress Echo to Real-Time Myocardial Contrast Stress Echo NCT00575549Expanded accessNo longer availableUniversity of Nebraska
Humanitarian Device Exemption NCT00580658Expanded accessApproved for marketingVanderbilt University Medical Center
PFO ACCESS Registry NCT00583401Expanded accessNo longer availableAbbott Medical Devices
Emergency/Compassionate Use - Membranous VSD Occluder NCT00583505Expanded accessNo longer availableAbbott Medical Devices
Emergency/Compassionate Use - AMPLATZER Duct Occluder NCT00583583Expanded accessNo longer availableAbbott Medical Devices
Emergency/Compassionate Use PFO Occluder NCT00584064Expanded accessApproved for marketingAbbott Medical Devices
Emergency/Compassionate Use - Muscular VSD Occluder NCT00590382Expanded accessApproved for marketingAbbott Medical Devices
Erwinase Master Treatment Protocol NCT00590915Expanded accessNo longer availablePhoenix Children's Hospital

972 more trials match. See them on Pharma Observatory

Expanded Access Program for Treatment With Ecopipam for Tourette's Disorder NCT07093541Status changeAvailable to Temporarily not availableOctober 15, 2026

Go deeper on Pharma Observatory

Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.

Visit Pharma Observatory